Hervana Bio News
3 articles
growth-positive
The Israeli startup developing the first new, non-hormonal contraceptive in 60 years | CTech
Hervana Bio, a biopharmaceutical company, is developing a non-hormonal contraceptive with added protection against sexually transmitted infections (STIs). The contraceptive is based on lactobacilli, a bacteria found in the female reproductive tract, and is currently in the trial stage with a reported 100% efficacy rate. The contraceptive also has the potential to prevent STIs. The company is seeking additional funding to further develop and market the product. The contraceptive market is valued at $20 billion and is expected to reach $25 billion by 2027.
Investment
growth-positive
Hervana Bio Founder and CEO Dr. Rachel Teitelbaum Provides Update on Female Contraceptive Development at Microbiome EU Summit
Hervana Bios CEO, Rachel Teitelbaum, has presented an update on the development of HER-102, a reversible female contraceptive, at the Microbiome Drug Development Summit Europe. The contraceptive harnesses the power of antibodies to prevent pregnancy and protect against sexually transmitted infections, including HIV. The contraceptive effect has been shown to be fully reversible, with no negative effects in preliminary toxicology studies. Hervana Bio is an Israeli-based biopharmaceutical company dedicated to innovating products in womens health.
InvestmentExpand
growth-positive
Bill Gates Grants Hervana $1M for Contraceptive
Hervana has been awarded a $1 million grant from the Bill & Melinda Gates Foundation for the development of a long-acting, non-hormonal contraceptive platform technology. The grant will support the creation of a vaginal suppository that only needs to be applied once or twice a month, providing a low-cost and non-invasive contraceptive option. The CEO and founder of Hervana, Rachel Teitelbaum, highlights the need for a contraceptive free of health risks and medical procedures, especially in developing countries where there is a lack of accessible options. The Gates Foundation is excited about this application for the developing world, as there are over 220 million women without access to effective contraception and 50 million abortions per year in the developing world.
Customers